Fasting Mimicking Diet and Autophagy

Diet Clinical Trial

Official title:

Cellular Effects of Fasting Mimicking Diet In Humans: An Interventional, Randomized, Open Label, Parallel Assignment Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06115551
• Other study ID #: LNT22-017
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 2, 2023
• Est. completion date: April 30, 2024

Study information

• Verified date: April 2024
• Source: L-Nutra Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluates autophagy in circulating white blood cells from generally healthy human volunteers exposed to fasting mimicking diet (FMD), a 5-day dietary regimen.

Description:

Fasting-mimicking diet (FMD) was developed to mimic the endocrine and metabolic effects that water-only fasting, while providing a modest calories and essential nutrients. The health benefits of FMD are caused by several molecular mechanisms, including the reduction of body weight, ectopic fat storage, insulin levels, endogenous glucose production and IGF-1. Autophagy is a catabolic membrane-trafficking phenomenon observed in yeast and mammalian cells. Nutrient deprivation induces autophagy. Autophagy has been proposed to be a fundamental cellular process being linked to aging and the progression of age-related diseases. The objective of this study is to evaluate the effects of consuming two FMD formulations on the autophagy process in the cell.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: April 30, 2024
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

• Ability and willingness to provide written informed consent;

• Ability and willingness to perform the study tests and adhere to study protocol (to the best of the participant's knowledge);

• BMI 20-35 kg/m2 (inclusive) at screening;

Exclusion Criteria:

• Diabetes treatment other than diet or metformin monotherapy;

• History of gastric bypass;

• Subjects with recent weight loss (>5%), use of weight loss medication, participated in a weight loss program in the past 3 months;

• Type 1 diabetes (based on medical history provided at screening);

• Use of immune suppression drugs;

• Contraindication for study foods (special food needs and allergy);

• Women who are pregnant;

• Alcohol dependency (alcohol intake greater than two drinks per day for women and three drinks per day for men).

• Has any medical disease or condition that, in the opinion of the principal investigator (PI) or appropriate study personnel, precludes study participation* (*Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial);

Related Conditions & MeSH terms

• Autophagy
• Diet

Intervention

Combination Product:
• Fasting Mimicking Diet
FMD is a 5-day low calorie fasting-mimicking diet.

Locations

Country	Name	City	State
United States	The University of Texas Health Science Center at San Antonio	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
L-Nutra Inc	The University of Texas Health Science Center at San Antonio

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Autophagy flux	PBMCs will be prepared with or without Chloroquine (autophagy flux inhibitor). LC3BI to LC3BII conversion, the lipidation of MAP1LC3B/LC3B (microtubule-associated protein 1 light chain 3 ß), in the PBMCs will be accessed by western blot.; Autophagy-dependent degradation of SQSTM1/p62, a receptor and scaffold protein interacting with LC3 and ubiquitinated proteins, will be accessed by western blot.	Baseline to day 8
Secondary	Metabolomic change	Plasma will be analyzed by high throughput RNA sequencing for gene expression changes.	Baseline to day 8
Secondary	Autophagy-related gene expression	PBMCs will be prepared with or without Chloroquine (autophagy flux inhibitor). PBMC RNA samples will be analyzed using ultra high-performance liquid chromatography/tandem accurate mass spectrometry (UHPLC/MS/MS).	Baseline to day 8